Aprepitant 40 mg capsules provide targeted prevention of chemotherapy-induced nausea and vomiting by blocking neurokinin-1 (NK1) receptors involved in vomiting reflex pathways. This formulation is designed for convenient single-dose administration, facilitating adherence to antiemetic treatment protocols. When used as part of a combination regimen with other antiemetics, Aprepitant improves patient comfort and quality of life during cancer therapy by significantly reducing both acute and delayed nausea. Its expert use supports optimal management of gastrointestinal side effects, helping patients maintain treatment schedules and overall well-being.